Description: GENinCode Plc, a cardiovascular disease company, focuses on predictive genetics for the prevention of cardiovascular disease. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The companyÂs invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. It operates business in Europe and Latin America. The company was incorporated in 2018 and is based in Oxford, the United Kingdom.
Home Page: www.genincode.com
GENI Technical Analysis
Oxford Science Park
Oxford,
OX4 4GP
United Kingdom
Phone:
44 1865 955 847
Officers
| Name | Title |
|---|---|
| Mr. Matthew Heaton Walls | CEO & Director |
| Mr. Jordi Puig Gilberte | COO & Director |
| Mr. Paul Andrew Peter Foulger | CFO & Director |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 44.2526 |
| Price-to-Sales TTM: | 31.7567 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |